Emerging data suggest this peptide, a dual agonist targeting both the gut-brain axis and another hormone, could represent a significant advancement for weight management . Initial clinical investigations have shown substantial decreases in visceral tissue, conceivably exceeding current weight-loss medications . However , additional study is needed